Monthly Archives:

SChLAP1 Highly Prognostic Biomarker for Disease Progression

Bethesda, Maryland—SChLAP1 (Secondary Chromosome Locus Associated with Prostate 1) is a highly predictive biomarker for the prognosis of metastatic progression in patients with prostate cancer, according to study results presented at the 15th Annual Meeting of the Society for Urologic Oncology. SChLAP1 is a recently identified long noncoding RNA (lncRNA) gene. According to R. Jeffrey Karnes, MD, and colleagues, the ... Read More »

Overall Survival in mCRPC Patients Improved with Abiraterone plus Prednisone

Bethesda, Maryland—Final analysis of results of the COU-AA-302 trial demonstrated that patients who received abiraterone acetate (AA) plus prednisone (P) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) had statistically significant improvement in overall survival. Results also showed that AA plus P is safe and effective in the long term. Those were the main takeaways from a presentation at ... Read More »

A Conversation with Fred Saad, MD, FRCSC

A Conversation with Fred Saad, MD, FRCSC Fred Saad, MD, FRCSC, is professor and chief of urology and director of G-U oncology at the University of Montreal Hospital Centers. He holds the University of Montreal Endowed Chair in Prostate Cancer Research and is director of the molecular oncology research lab in Prostate Cancer at the Montreal Cancer Institute. He is ... Read More »

Sequential Treatment with Sipuleucel-T followed by Enzalutamide

Amelia Island, Florida—Recent study results demonstrated a “promising effect” using sequential sipuleucel-T immunotherapy followed by enzalutamide for metastatic castration resistant prostate cancer (mCRPC). Sipuleucel-T was the first autologous cellular vaccine approved by the US FDA. The study was conducted by Christopher Pieczonka, MD, and colleagues. Results were reported during a poster session at the 66th NSAUA Annual Meeting in November. ... Read More »

Zytiga® + Low-Dose Predisone Lowers PSA Levels in MO-CRPC Patients

Maui—In the IMAAGEN  (Impact of Abiraterone Acetate in Prostate Specific Antigen) core study, patients with non-metastatic castration-resistant prostate cancer (MO-CRPC) had statistically significant reductions in prostate-specific antigen (PSA) levels at 6 months with a therapy regimen of abiraterone acetate (Zytiga®) plus prednisone (5 mg twice daily). The primary end point was the proportion of patients with a ≥50% reduction in ... Read More »

A Conversation with E. David Crawford, MD

The IMAAGEN Trial David Crawford, MD, is the Distinguished Endowed Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. He also serves as the Practice Director for the Urologic Oncology clinic. He was the lead author on the report from the Prostate Cancer ... Read More »